Andrew Fraley
Chief Innovation & Strategy Officer - Board Observer Sunrise Bioventures
Andrew Fraley is the Founding and Managing Partner of Sunrise BioVentures. A prolific company builder, he is a serial entrepreneur and scientific innovator with deep expertise in oligonucleotide therapeutics and gene editing. He is the founder and former CTO of Korro Bio and a co-founder of Trucode Gene Repair and Triplet Therapeutics. Andrew also serves in fractional C-suite roles for Radar Therapeutics and Shift Bioscience and is a Council Member of the Marine Biological Laboratory. Previously, he was Head of Chemistry at Moderna and an Entrepreneur-in-Residence at Atlas Venture. He holds a postdoctoral fellowship in bioorganic chemistry.
Seminars
The RNAi therapeutics landscape is rapidly evolving, with breakthroughs in delivery, efficacy, and commercialization reshaping investor expectations. Key discussion points will include clinical differentiation, market potential, and exit strategies, offering a reality check on valuation drivers and red flags.
- Prioritizing delivery platform versatility as a key value driver, enabling investors to back RNAi companies with broad therapeutic applicability
- Assessing clinical milestones beyond knockdown efficiency, including durability and patient-centric endpoints, to identify therapies with superior commercial potential
- Balancing platform validation with indication selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success
